Thanks to our BMT CTN study participants, we are able to do important research studies using blood and marrow transplant or cell therapies. Thank you for contributing to the incredible progress that has been made. We couldn’t do it without you.
On this page you can find easy-to-read summaries of the results of those studies. You may navigate within the drop downs to view the information. See Enrolling Studies page for studies that are enrolling patients.
This section under construction.
For questions, please contact bmtctnac@emmes.com.
This section under construction.
For questions, please contact bmtctnac@emmes.com.
Gilteritinib after transplant for patients with acute myeloid leukemia (AML) with FLT3 mutation (BMT CTN 1506)
This study helped us learn more about giving the medicine gilteritinib after transplant for patients who have FLT3 AML. There were around 356 participants from 147 transplant centers in this study.
If you were a part of this study and have questions about your participation, please contact your study doctor or the study staff. Thank you for your impact on clinical research!
This section under construction.
For questions, please contact bmtctnac@emmes.com.
This section under construction.
For questions, please contact bmtctnac@emmes.com.
Half-Matched (Haploidentical) bone marrow transplant for patients with severe sickle cell disease (BMT CTN 1507)
This study helped us learn if haploidentical transplants are safe for patients who have severe sickle cell disease. There were 95 participants (54 adults and 41 children) from 28 transplant centers in this study.
Study results: coming soon!
If you or your child were a part of this study and have questions about your participation, please contact your study doctor or the study staff. Thank you for your impact on clinical research!
This section under construction.
For questions, please contact bmtctnac@emmes.com.